NEW YORK (
) has been downgraded by TheStreet Ratings from hold to sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
Highlights from the ratings report include:
- The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Life Sciences Tools & Services industry. The net income has significantly decreased by 205.6% when compared to the same quarter one year ago, falling from -$0.22 million to -$0.66 million.
- The company's current return on equity has slightly decreased from the same quarter one year prior. This implies a minor weakness in the organization. Compared to other companies in the Life Sciences Tools & Services industry and the overall market, STRATEGIC DIAGNOSTICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
- Net operating cash flow has significantly decreased to -$0.66 million or 213.80% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- In its most recent trading session, SDIX has closed at a price level that was not very different from its closing price of one year earlier. This is probably due to its weak earnings growth as well as other mixed factors. This company's share value has not moved any higher or lower since its value 12 months ago, and we feel the risks associated with investing in this company will outweigh any potential future gains.
- STRATEGIC DIAGNOSTICS INC has exprienced a steep decline in earnings per share in the most recent quarter in comparison to its performance from the same quarter a year ago. This company has not demonstrated a clear trend in earnings over the past two years, making it difficult to accurately predict earnings for the coming year. During the past fiscal year, STRATEGIC DIAGNOSTICS INC continued to lose money by earning -$0.04 versus -$0.08 in the prior year.
Strategic Diagnostics Inc., a biotechnology company, develops, commercializes, and markets proprietary products, services, and solutions for the pharmaceutical, biotechnology, diagnostics, food safety, and environmental markets. Strategic has a market cap of $39.3 million and is part of the
industry. Shares are up 6.3% year to date as of the close of trading on Wednesday.
You can view the full
or get investment ideas from our